{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:34:18Z","timestamp":1761489258267},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/mop.0b013e32836565ac","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T09:28:50Z","timestamp":1384507730000},"page":"682-688","source":"Crossref","is-referenced-by-count":16,"title":["Current advances in drug development in spinal muscular atrophy"],"prefix":"10.1097","volume":"25","author":[{"given":"Priyamvada","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy K.M.","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.7910982","article-title":"De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.","volume":"264","author":"Melki","year":"1994","journal-title":"Science"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene.","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of72,400 specimens.","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","article-title":"Classification of spinal muscular atrophies.","volume":"1","author":"Pearn","year":"1980","journal-title":"Lancet"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0960-8966(99)00016-4","article-title":"59th ENMC International Workshop: spinal muscular atrophies - recent progress and revised diagnostic criteria 17-19 April. Soestduinen, The Netherlands.","volume":"9","author":"Zerres","year":"1999","journal-title":"Neuromuscul Disord"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution.","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscul Disord"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: clinical classification and disease heterogeneity.","volume":"22","author":"Russman","year":"2007","journal-title":"J Child Neurol"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN.","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum Mol Genet"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene.","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1093\/emboj\/cdf585","article-title":"Assisted RNP assembly: SMN and PRMT5 complexes cooperate in the formation of spliceosomal UsnRNPs.","volume":"21","author":"Meister","year":"2002","journal-title":"EMBO J"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1074\/jbc.M110141200","article-title":"Purification of native survival of motor neurons complexes and identification of Gemin6 as a novel component.","volume":"277","author":"Pellizzoni","year":"2002","journal-title":"J Biol Chem"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate.","volume":"98","author":"Chang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1083\/jcb.200303168","article-title":"Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding.","volume":"162","author":"McWhorter","year":"2003","journal-title":"J Cell Biol"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/0883073807305671","article-title":"Fishing for a mechanism: using zebrafish to understand spinal muscular atrophy.","volume":"22","author":"Beattie","year":"2007","journal-title":"J Child Neurol"},{"key":"R15-9-20210206","first-page":"289","article-title":"Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes.","volume":"48","author":"Rossoll","year":"2009","journal-title":"Results Probl Cell Differ"},{"key":"R16-9-20210206","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1093\/hmg\/ddp310","article-title":"Zebrafish survival motor neuron mutants exhibit presynaptic neuromuscular junction defects.","volume":"18","author":"Boon","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice.","volume":"29","author":"Kong","year":"2009","journal-title":"J Neurosci"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1523\/JNEUROSCI.4496-09.2010","article-title":"Altered intracellular Ca2homeostasis in nerve terminals of severe spinal muscular atrophy mice.","volume":"30","author":"Ruiz","year":"2010","journal-title":"J Neurosci"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.nmd.2010.06.010","article-title":"Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for spinal muscular atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing.","volume":"20","author":"Voigt","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy.","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum Mol Genet"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2012.09.011","article-title":"SMN is required for sensory-motor circuit function in Drosophila.","volume":"151","author":"Imlach","year":"2012","journal-title":"Cell"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/0883073809332702","article-title":"Clinical outcome measures in spinal muscular atrophy.","volume":"24","author":"Montes","year":"2009","journal-title":"J Child Neurol"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","article-title":"The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation.","volume":"7","author":"Main","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith functional motor scale for SMA II and III patients.","volume":"17","author":"OHagen","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy.","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.0b013e3181eccf8f","article-title":"Assessing spinal muscular atrophy with quantitative ultrasound.","volume":"75","author":"Wu","year":"2010","journal-title":"Neurology"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/01.wnl.0000201929.56928.13","article-title":"SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials.","volume":"66","author":"Sumner","year":"2006","journal-title":"Neurology"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nurx.2006.01.010","article-title":"Therapeutics development for spinal muscular atrophy.","volume":"3","author":"Sumner","year":"2006","journal-title":"NeuroRx"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/j.1471-4159.2009.06084.x","article-title":"The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.","volume":"109","author":"Lunke","year":"2009","journal-title":"J Neurochem"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression.","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells.","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well known drug as a potential therapy for spinal muscular atrophy.","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS One"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy.","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy.","volume":"14","author":"Mercuri","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy.","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients nonresponsive to valproate.","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.","volume":"58","author":"Grzeschik","year":"2005","journal-title":"Ann Neurol"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2007.11.012","article-title":"The effect of hydroxyurea in spinal muscular atrophy cells and patients.","volume":"268","author":"Liang","year":"2008","journal-title":"J Neurol Sci"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy.","volume":"75","author":"Chen","year":"2010","journal-title":"Neurology"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells.","volume":"45","author":"Angelozzi","year":"2008","journal-title":"J Med Genet"},{"key":"R44-9-20210206","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design.","volume":"47","author":"Tiziano","year":"2010","journal-title":"J Med Genet"},{"key":"R45-9-20210206","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.","volume":"19","author":"Butchbach","year":"2010","journal-title":"Hum Mol Genet"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/ddl482","article-title":"Stat5 constitutive activation rescues defects in spinal muscular atrophy.","volume":"16","author":"Ting","year":"2007","journal-title":"Hum Mol Genet"},{"key":"R48-9-20210206","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1172\/JCI46276","article-title":"Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.","volume":"121","author":"Farooq","year":"2011","journal-title":"J Clin Invest"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1523\/JNEUROSCI.0950-09.2009","article-title":"Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.","volume":"29","author":"Williams","year":"2009","journal-title":"J Neurosci"},{"key":"R50-9-20210206","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1261\/rna.2154310","article-title":"An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in premRNA splicing.","volume":"16","author":"Singh","year":"2010","journal-title":"RNA"},{"key":"R51-9-20210206","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"R52-9-20210206","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.","volume":"21","author":"Porensky","year":"2012","journal-title":"Hum Mol Genet"},{"key":"R53-9-20210206","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"R54-9-20210206","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"R55-9-20210206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study.","volume":"18","author":"Merlini","year":"2003","journal-title":"J Child Neurol"},{"key":"R57-9-20210206","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature07677","article-title":"Induced pluripotent stem cells from a spinal muscular atrophy patient.","volume":"457","author":"Ebert","year":"2009","journal-title":"Nature"},{"issue":"Pt 2","key":"R58-9-20210206","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/brain\/awp318","article-title":"Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice.","volume":"133","author":"Corti","year":"2010","journal-title":"Brain"},{"key":"R59-9-20210206","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1517\/14712598.2012.711306","article-title":"Update on gene and stem cell therapy approaches for spinal muscular atrophy.","volume":"12","author":"Donnelly","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"R60-9-20210206","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"R61-9-20210206","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.","volume":"120","author":"Passini","year":"2010","journal-title":"J Clin Invest"},{"key":"R62-9-20210206","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2011.11.121","article-title":"Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy.","volume":"417","author":"Glascock","year":"2012","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0b013e32836565ac","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:43:28Z","timestamp":1620963808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201312000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e32836565ac","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}